abaloparatide vs denosumab
Side-by-side comparison of abaloparatide and denosumab Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tymlos
Prolia, Xgeva
Tymlos is a medicine to treat osteoporosis. It helps make your bones stronger and less likely to break.
Stoboclo is a medicine that helps to treat osteoporosis and increase bone mass. It works by blocking a protein that breaks down bone.
Tymlos treats osteoporosis in women after menopause and in men. It is for people who have a high chance of breaking a bone. This includes those who have already had a bone break due to osteoporosis or have other risk factors. It can also be used if other osteoporosis treatments did not work or could not be tolerated.
Stoboclo treats osteoporosis in women after menopause who are at high risk for fractures. It also helps increase bone mass in men with osteoporosis who are at high risk for fractures. Stoboclo can also treat bone loss caused by steroid medicines or cancer treatments that lower hormone levels. It helps to make your bones stronger and less likely to break.
Tymlos is similar to a natural hormone in your body. It helps your body build new bone. This makes your bones stronger and less likely to break.
Stoboclo blocks a protein called RANKL. RANKL tells your body to break down bone. By blocking RANKL, Stoboclo slows down bone loss and helps to increase bone mass.
- • High calcium in your urine
- • Feeling dizzy
- • Feeling sick to your stomach
- • Headache
- • Feeling your heart beat fast or irregularly
- • Back pain
- • Pain in your arms or legs
- • Muscle and bone pain
- • High cholesterol
- • Bladder infection
- Headache 4,180
- Feeling sick to your stomach 3,222
- Feeling dizzy 3,122
- Feeling tired 2,742
- Increased heart rate 2,139
- Using the medicine for something it's not approved for 36,484
- Death 19,930
- Joint pain 8,682
- Bone damage in the jaw 8,425
- Feeling tired 7,481
Tymlos may increase the risk of bone cancer (osteosarcoma). You should not take this medicine if you have certain conditions that increase this risk. These include Paget's disease, bone cancer, radiation treatment to your bones, or certain hereditary disorders. If you have symptoms of feeling dizzy, palpitations, tachycardia, or nausea, you should sit or lie down.
Stoboclo can cause very low calcium levels in people with serious kidney disease, especially those on dialysis. This can lead to hospitalization, life-threatening problems, and even death. If you have kidney problems, your doctor should check you for mineral and bone disorders before you start Stoboclo. You should be watched closely by a doctor who knows how to treat these problems.
Tymlos is not for women who could get pregnant. It is not known if Tymlos can harm an unborn baby or pass into breast milk.
Stoboclo can harm your unborn baby. You should not take Stoboclo if you are pregnant. If you are able to get pregnant, you should use birth control while taking Stoboclo and for at least 5 months after your last dose.
How to Read This abaloparatide vs denosumab Comparison
abaloparatide is classified in the PTHrP Analog drug class, while denosumab sits within the RANK Ligand Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, abaloparatide has 15,405 submissions while denosumab has 81,002. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between abaloparatide and denosumab — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.